24 November 2022
One of the effective tools for achieving technological sovereignty of the domestic pharmaceutical industry may be the creation of a consortium for the production of pharmaceutical, chemical and biotechnological raw materials to meet the needs of drug production. State participation is an important condition for the creation of such a structure. This was stated by Vladislav Shestakov, the director of the FBI “State Institute of Drugs and Good Practices” of the Ministry of Industry and Trade of Russia at the plenary session of the Pharmtech & Ingredients industry exhibition.
“Stimulating the development of domestic industry in the current context requires comprehensive solitions. It is impossible to solve the problem of import dependence without providing pharmaceutical manufacturers with sufficient raw materials for production. The solution may be the creation of a specialized chemical raw materials consortium with state participation. Later on, such an association will contribute to the growth of the domestic pharmaceutical industry and enhance its position in international markets,” Shestakov said.
As an example of a similar association, he cited the EUROAPI company created by Sanofi in 2020, during the COVID-19 pandemic, which combines industrial and commercial activities, as well as a service for creating unique custom-made molecules. “Now it includes a number of sites that produce substances and supply them to Europe and beyond,” Vladislav Shestakov said.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024